Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.58% | -56.34% | -55.47% | -9.86% | 37.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.58% | -56.34% | -55.47% | -9.86% | 37.97% |
| Cost of Revenue | -56.90% | -43.08% | 89.11% | -12.11% | 74.70% |
| Gross Profit | -48.58% | -67.85% | -113.74% | -8.63% | 15.69% |
| SG&A Expenses | 32.23% | -2.64% | 71.00% | 64.72% | 29.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.55% | -7.11% | 73.10% | 54.59% | 33.99% |
| Operating Income | -49.91% | -8.40% | -160.42% | -92.69% | -32.35% |
| Income Before Tax | -1,168.40% | 67.28% | -111.56% | -100.81% | 200.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,168.40% | 67.28% | -111.56% | -100.81% | 200.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,168.40% | 67.28% | -111.56% | -100.81% | 200.68% |
| EBIT | -49.91% | -8.40% | -160.42% | -92.69% | -32.35% |
| EBITDA | -50.70% | -8.34% | -161.75% | -93.17% | -32.08% |
| EPS Basic | -- | 50.00% | -- | -- | -- |
| Normalized Basic EPS | -- | 100.00% | -- | -- | -- |
| EPS Diluted | -- | 50.00% | -- | -- | -- |
| Normalized Diluted EPS | -- | 100.00% | -- | -- | -- |
| Average Basic Shares Outstanding | 4.18% | 4.35% | 1.81% | 2.08% | 1.12% |
| Average Diluted Shares Outstanding | -78.62% | 4.35% | 1.81% | 2.08% | 392.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |